UDP-glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin

Drug Metabolism and Pharmacokinetics

Volumn 30, Issue 1, 2015, Pages 82-88

  Fujiwara, Ryoichi ^a   Sumida, Kyohei ^a   Kutsuno, Yuki ^a   Sakamoto, Masaya ^a   Itoh, Tomoo ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Acyl glucuronide; Hepatotoxicity; Trovafloxacin; UDP Glucuronosyltransferase; UGT1A1

Indexed keywords

GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B7; TROVAFLOXACIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; GLUCURONIDE; NAPHTHYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE; UGT1A1 ENZYME;

ANIMAL CELL; ARTICLE; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; MOUSE; NONHUMAN; RAT; SMALL INTESTINE; ANIMAL; DRUG-INDUCED LIVER INJURY; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; IN VITRO STUDY; INTESTINE; METABOLISM; RABBIT; SPECIES DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG-INDUCED LIVER INJURY; FLUOROQUINOLONES; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; IN VITRO TECHNIQUES; INTESTINES; MICE; MICROSOMES, LIVER; NAPHTHYRIDINES; POLYMORPHISM, GENETIC; RABBITS; RATS; SPECIES SPECIFICITY;

EID: 84924939994     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.1016/j.dmpk.2014.09.003     Document Type: Article

References (32)

1. G.J. Dutton Acceptor substrates of UDP glucuronosyltransferase and their assay G.J. Dutton, Glucuronidation of drugs and other compounds 1980 CRC Press Boca Raton, FL 69 78
2. P.I. Mackenzie, K.W. Bock, B. Burchell, C. Guillemette, S. Ikushiro, and T. Iyanagi Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily Pharmacogenet Genomics 15 2005 677 685
3. R. Meech, and P.I. Mackenzie UGT3A: novel UDP-glycosyltransferases of the UGT superfamily Drug Metab Rev 42 2010 45 54
4. J.A. Williams, R. Hyland, B.C. Jones, D.A. Smith, S. Hurst, and T.C. Goosen Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios Drug Metab Dispos 32 2004 1201 1208
5. R. Meech, J.O. Miners, B.C. Lewis, and P.I. Mackenzie The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily Pharmacol Ther 134 2012 200 218
6. P.I. Mackenzie, A. Rogers, J. Treloar, B.R. Jorgensen, J.O. Miners, and R. Meech Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase J Biol Chem 283 2008 36205 36210
7. P.I. MacKenzie, A. Rogers, D.J. Elliot, N. Chau, J.A. Hulin, and J.O. Miners The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution Mol Pharmacol 79 2011 472 478
8. R.H. Mathijssen, R.J. van Alphen, J. Verweij, W.J. Loos, K. Nooter, and G. Stoter Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 7 2001 2182 2194
9. Y. Ando, H. Saka, M. Ando, T. Sawa, K. Muro, and H. Ueoka Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res 60 2000 6921 6926
10. N.R. Pumford, T.G. Myers, J.C. Davila, R.J. Highet, and L.R. Pohl Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac Chem Res Toxicol 6 1993 147 150
11. T.D. Gootz, and P.R. McGuirk New quinolones in development Expert Opin Investig Drugs 3 1994 93 114
12. D.K. Dalvie, N. Khosla, and J. Vincent Excretion and metabolism of trovafloxacin in humans Drug Metab Dispos 25 1997 423 427
13. M. Pirmohamed, S. Madden, and B.K. Park Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism Clin Pharmacokinet 31 1996 215 230
14. T. Koga, R. Fujiwara, M. Nakajima, and T. Yokoi Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes Drug Metab Dispos 39 2011 54 60
15. Y. Kutsuno, T. Itoh, R.H. Tukey, and R. Fujiwara Glucuronidation of drugs and drug-induced toxicity in humanized UDP-glucuronosyltransferase 1 mice Drug Metab Dispos 42 2014 1146 1152
16. R.H. Tukey, and C.P. Strassburg Human UDP-glucuronosyltransferases: metabolism, expression and disease Annu Rev Pharmacol Toxicol 40 2000 581 616
17. A. Nakamura, M. Nakajima, H. Yamanaka, R. Fujiwara, and T. Yokoi Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines Drug Metab Dispos 36 2008 1461 1464
18. K. Sumida, M. Kawana, E. Kouno, T. Itoh, S. Takano, and T. Narawa Importance of UDP-glucuronosyltransferase 1A1 expression in skin and its induction by UVB in neonatal hyperbilirubinemia Mol Pharmacol 84 2013 679 686
19. T. Izukawa, M. Nakajima, R. Fujiwara, H. Yamanaka, T. Fukami, and M. Takamiya Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers Drug Metab Dispos 37 2009 1759 1768
20. S. Ohno, and S. Nakajin Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction Drug Metab Dispos 37 2009 32 40
21. S. Ohtsuki, O. Schaefer, H. Kawakami, T. Inoue, S. Liehner, and A. Saito Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities Drug Metab Dispos 40 2012 83 92
22. J.H. Chang, E. Plise, J. Cheong, Q. Ho, and M. Lin Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia Mol Pharm 10 2013 3067 3075
23. M.I. Lucena, R.J. Andrade, L. Rodrigo, J. Salmerón, A. Alvarez, and M.J. Lopez-Garrido Trovafloxacin-induced acute hepatitis Clin Infect Dis 30 2000 400 401
24. A. Shibuya, T. Itoh, R.H. Tukey, and R. Fujiwara Impact of fatty acids on human UDP-glucuronosyltransferase 1A1 activity and its expression in neonatal hyperbilirubinemia Sci Rep 3 2013 2903
25. R. Fujiwara, M. Nakajima, H. Yamanaka, M. Katoh, and T. Yokoi Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities Drug Metab Dispos 35 2007 1781 1787
26. R. Fujiwara, M. Nakajima, H. Yamanaka, A. Nakamura, M. Katoh, and S. Ikushiro Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms Drug Metab Dispos 35 2007 747 757
27. M. Nakajima, E. Tanaka, J.T. Kwon, and T. Yokoi Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes Drug Metab Dispos 30 2002 1484 1490
28. Y. Ishii, S. Takeda, and H. Yamada Modulation of UDP-glucuronosyltransferase activity by protein-protein association Drug Metab Rev 42 2010 145 158
29. M.J. Liguori, M.G. Anderson, S. Bukofzer, J. McKim, J.F. Pregenzer, and J. Retief Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin Hepatology 41 2005 177 186
30. M. Wang, M.D. Gorrell, G.W. McGaughan, and R.G. Dickinson Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac Life Sci 68 2001 785 797
31. A. Ding, J.C. Ojingwa, A.F. McDonagh, A.L. Burlingame, and L.Z. Benet Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry Proc Natl Acad Sci U S A 90 1993 3797 3801
32. T. Miyashita, K. Kimura, T. Fukami, M. Nakajima, and T. Yokoi Evaluation and mechanistic analysis of the cytotoxicity of the acyl glucuronide of nonsteroidal anti-inflammatory drugs Drug Metab Dispos 42 2014 1 8